Search

Darunavir

[L9227] Darunavir is being studied as a possible treatment for SARS-CoV-2, the coronavirus responsible for COVID-19, due to in vitro evidence supporting its ability to combat this infection. … [L9227] As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy.[A2278,A2281] It was initially approved by the FDA in 2006.

Tezacaftor

[L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018. … [L4894] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion

Ruxolitinib

[A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012.

Phentermine

[A174367] Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. … [A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine.

Arbutin

Arbutin was shown to be less cytotoxic to melanocytes in culture compared to [DB09526] [A32942]. … It has also been used as an anti-infective for the urinary system as well as a diuretic [F43].

Spanlecortemlocel

Bezlotoxumab

[L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection. … [L46976] On November 22, 2016, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of a marketing authorization.

Nilotinib

A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec … ), another tyrosine kinase inhibitor used as a first-line treatment for CML.

Candesartan cilexetil

Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents … Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension.